Vanguard Group’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $190M | Buy |
7,962,874
+1,333,421
| +20% | +$27.2M | ﹤0.01% | 1574 |
|
|
2025
Q3 | $90.2M | Buy |
6,629,453
+73,210
| +1% | +$761K | ﹤0.01% | 1902 |
|
|
2025
Q2 | $53.4M | Sell |
6,556,243
-131,557
| -2% | -$1.12M | ﹤0.01% | 2086 |
|
|
2025
Q1 | $52.5M | Buy |
6,687,800
+1,298,584
| +24% | +$15.1M | ﹤0.01% | 2079 |
|
|
2024
Q4 | $80.2M | Sell |
5,389,216
-79,539
| -1% | -$1.3M | ﹤0.01% | 1954 |
|
|
2024
Q3 | $83.6M | Buy |
5,468,755
+211,429
| +4% | +$3.33M | ﹤0.01% | 1958 |
|
|
2024
Q2 | $80.1M | Buy |
5,257,326
+466,082
| +10% | +$7.52M | ﹤0.01% | 1942 |
|
|
2024
Q1 | $90.5M | Buy |
4,791,244
+110,528
| +2% | +$1.91M | ﹤0.01% | 1916 |
|
|
2023
Q4 | $89.4M | Buy |
4,680,716
+186,898
| +4% | +$2.99M | ﹤0.01% | 1923 |
|
|
2023
Q3 | $80.7M | Buy |
4,493,818
+61,040
| +1% | +$1.23M | ﹤0.01% | 1919 |
|
|
2023
Q2 | $90M | Buy |
4,432,778
+9,119
| +0.2% | +$174K | ﹤0.01% | 1912 |
|
|
2023
Q1 | $80.7M | Buy |
4,423,659
+50,482
| +1% | +$965K | ﹤0.01% | 1925 |
|
|
2022
Q4 | $90.4M | Sell |
4,373,177
-84,007
| -2% | -$2.31M | ﹤0.01% | 1857 |
|
|
2022
Q3 | $117M | Buy |
4,457,184
+173,854
| +4% | +$4.6M | ﹤0.01% | 1692 |
|
|
2022
Q2 | $109M | Buy |
4,283,330
+771,216
| +22% | +$18.9M | ﹤0.01% | 1765 |
|
|
2022
Q1 | $111M | Buy |
3,512,114
+85,778
| +3% | +$2.87M | ﹤0.01% | 1882 |
|
|
2021
Q4 | $139M | Buy |
3,426,336
+959,857
| +39% | +$37.2M | ﹤0.01% | 1800 |
|
|
2021
Q3 | $86M | Buy |
2,466,479
+37
| +0% | +$1.15K | ﹤0.01% | 2067 |
|
|
2021
Q2 | $67.7M | Sell |
2,466,442
-58,407
| -2% | -$1.67M | ﹤0.01% | 2208 |
|
|
2021
Q1 | $70.9M | Buy |
2,524,849
+177,225
| +8% | +$6.17M | ﹤0.01% | 2124 |
|
|
2020
Q4 | $60.9M | Buy |
2,347,624
+141,684
| +6% | +$3.43M | ﹤0.01% | 2102 |
|
|
2020
Q3 | $37.8M | Buy |
2,205,940
+12,820
| +0.6% | +$286K | ﹤0.01% | 2151 |
|
|
2020
Q2 | $54.3M | Buy |
2,193,120
+668,026
| +44% | +$18M | ﹤0.01% | 1973 |
|
|
2020
Q1 | $21.2M | Buy |
1,525,094
+127,844
| +9% | +$1.59M | ﹤0.01% | 2254 |
|
|
2019
Q4 | $14.1M | Buy |
1,397,250
+1,988
| +0.1% | +$16.7K | ﹤0.01% | 2692 |
|
|
2019
Q3 | $12.7M | Buy |
1,395,262
+302,841
| +28% | +$2.43M | ﹤0.01% | 2704 |
|
|
2019
Q2 | $8.69M | Sell |
1,092,421
-69,525
| -6% | -$696K | ﹤0.01% | 2938 |
|
|
2019
Q1 | $14.5M | Buy |
1,161,946
+47,744
| +4% | +$518K | ﹤0.01% | 2646 |
|
|
2018
Q4 | $12M | Buy |
1,114,202
+661,793
| +146% | +$7.73M | ﹤0.01% | 2678 |
|
|
2018
Q3 | $6.31M | Buy |
452,409
+12,511
| +3% | +$160K | ﹤0.01% | 3146 |
|
|
2018
Q2 | $5.38M | Buy |
439,898
+379,898
| +633% | +$5.96M | ﹤0.01% | 3194 |
|
|
2018
Q1 | $927K | Buy |
+60,000
| New | +$999K | ﹤0.01% | 3659 |
|
Other funds holding RCUS
GS
SCM
WP
SL
Vanguard Group's RCUS Position: Q4 2025 in Review
Vanguard Group increased its Arcus Biosciences (RCUS) stake by 20% in Q4 2025, buying an estimated $27.2M and bringing the position to 7,962,874 shares worth $190M. The position accounts for ﹤0.01% of the portfolio, ranked #1574.
Vanguard Group first reported a position in RCUS in Q1 2018 and has held it in 32 quarters since. 209 funds tracked by Wall St. Rank hold RCUS as of Q4 2025.
- Vanguard Group held 7,962,874 shares of Arcus Biosciences worth $190M as of Q4 2025.
- Vanguard Group bought 1,333,421 Arcus Biosciences shares in Q4 2025, an estimated $27.2M.
- Arcus Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1574 holding.
- Vanguard Group first reported a position in Arcus Biosciences in Q1 2018 and has held it in 32 quarters since.
- 209 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.